<DOC>
	<DOC>NCT00141349</DOC>
	<brief_summary>To determine the onset of action, safety and toleration of different formulations and doses of UK-369,003 in patients with erectile dysfunction. Patients should have been previously treated with PDE5 inhibitors and have been responders to the drugs. Duration of treatment is 4 weeks.</brief_summary>
	<brief_title>Assessment of Onset, Safety &amp; Toleration of UK-369,003 in Male Erectile Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Erectile Dysfunction</mesh_term>
	<criteria>Erectile dysfunction as defined by DSMIV. Patients should have been PDE5 inhibitor respondents Alpha blockers and Nitrates of any preparation</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2006</verification_date>
</DOC>